Merck’s Vioxx liability could reach $18 billion

Share this article:
Analysts have estimated that Merck's potential liability could reach $18 billion in lawsuits over its withdrawn COX-2 drug Vioxx, according to a report in today's Wall Street Journal.
A federal judge in New Orleans told lawyers yesterday that there could ultimately be up to 100,000 cases filed against Merck and that he could hear a case as early as this fall, the Journal report said.
The first cases are set to be heard in state courts – Texas in July and New Jersey in August – with a case in Alabama currently postponed. 
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.